Naratriptan Zydus (Naratriptan Hydrochloride)

Naratriptan, the active ingredient in Naratriptan Zydus, is a Triptan (selective 5-HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is used for the acute treatment of migraine attacks in adults. GNH USA supplies Naratriptan Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is indicated for migraine management. - Migraine without aura: provides rapid relief of headache and associated symptoms. - Migraine with aura: aborts attacks and reduces aura‑related discomfort. - Acute migraine attacks: shortens the duration of pain and improves functional ability.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Tingling or paresthesia: especially in extremities. - Drowsiness: increased sleepiness.

Serious or Rare Side Effects: - Chest pain or tightness: may indicate cardiac involvement. - Severe hypertension: sudden rise in blood pressure. - Serotonin syndrome: rare but potentially life‑threatening when combined with serotonergic agents. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Coronary vasospasm: constriction of coronary arteries. - Cardiac arrhythmia: irregular heart rhythm.

Before prescribing Naratriptan, clinicians should assess cardiovascular risk and other contraindications. - Cardiovascular disease: avoid use in patients with coronary artery disease, angina, or history of myocardial infarction. - Uncontrolled hypertension: do not use in patients with systolic >160 mmHg or diastolic >100 mmHg. - Hemiplegic or basilar migraine: contraindicated due to increased stroke risk. - Concomitant MAO inhibitors: avoid use within 14 days of MAOI therapy. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store below 25°C: keep in the original container, protect from moisture.

Naratriptan may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstriction. - Certain CYP1A2 inhibitors: may increase plasma levels.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: monitor for serotonin syndrome. - Antihypertensive agents: may enhance blood pressure lowering. - Oral contraceptives: may affect efficacy of migraine control. - CYP3A4 inhibitors: may modestly raise naratriptan concentrations.